Greg Wolf to Patient Selection
This is a "connection" page, showing publications Greg Wolf has written about Patient Selection.
Connection Strength
0.272
-
Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, Prince ME, Teknos TN, Chepeha DB, Hogikyan ND, McLean SA, Moyer J, Taylor JMG, Worden FP. Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2017 04 01; 143(4):355-366.
Score: 0.117
-
Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):869-74.
Score: 0.069
-
Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008 Jul 01; 26(19):3138-46.
Score: 0.063
-
Chinn SB, Spector ME, Bellile EL, Rozek LS, Lin T, Teknos TN, Prince ME, Bradford CR, Urba SG, Carey TE, Eisbruch A, Wolf GT, Worden FP, Chepeha DB. Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma. JAMA Otolaryngol Head Neck Surg. 2014 Feb; 140(2):134-42.
Score: 0.023